➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKesson
McKinsey
Moodys
AstraZeneca

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,347,243

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,347,243
Title: Acid soluble, pepsin resistant platelet aggregating material
Abstract:Acid soluble, pepsin resistant, platelet aggregating material isolated from equine arterial tissue by extraction with dilute aqueous acid, method of isolation and use to control bleeding.
Inventor(s): Schneider; Morris D. (Knoxville, TN)
Assignee: Research Corporation (New York, NY)
Application Number:06/292,200
Patent Claims:1. A method of preparing a hemostatic agent comprising the steps of:

(a) extracting cleansed, homogenized equine arterial tissue with dilute aqueous acid at from about 0.degree. C. to 5.degree. C.,

(b) dialyzing the extract against dilute acid,

(c) subjecting the retentate to proteolysis with pepsin, and

(d) precipitating the hemostatic agent by the addition of a water soluble salt to the resulting mixture.

2. The method of claim 1 wherein the arterial tissue is burro aortic tissue.

3. The method of claim 1 wherein the arterial tissue is horse aortic tissue.

4. The method of claim 1 wherein the acid is acetic acid for both extraction and dialysis.

5. The method of claim 2 wherein the acid is acetic acid for both extraction and dialysis.

6. The method of claim 3 wherein the acid is acetic acid for both extraction and dialysis.

7. An acid soluble, pepsin resistant, non-dialyzable, proteinaceous hemostatic agent isolated from equine arterial tissue characterized by the ability to enhance platelet aggregating activity in mammalian blood, stable for extended periods of time at temperatures as low as -85.degree. C., losing its platelet aggregating activity when exposed to collagenase at 37.degree. C. or when heated at 100.degree. C. for fifteen minutes; containing the following average number of amino acid residues per 1,000 total amino acid residues:

which on SDS-PAGE electrophoresis products bands characteristic of the following molecular weights:

322,000

300,000

250,000

220,000

163,000

132,000

116,000

100,000

61,500

51,500

45,000

36,000

8. A hemostatic agent of claim 7 in a pharmaceutically acceptable carrier.

9. A hemostatic agent of claim 7 in an externally administerable pharmaceutical carrier.

10. A hemostatic agent of claim 7 in a balanced salt solution.

11. A hemostatic agent of claim 7 in water.

12. A method of stimulating platelet aggregation in mammalian plasma or whole blood which comprises contacting said plasma or whole blood with an amount which is effective to stimulate platelet aggregation of an acid soluble, pepsin resistant, non-dialyzable, proteinaceous hemostatic agent isolated from equine arterial tissue characterized by the ability to enhance platelet aggregating activity in mammalian blood, stable for extended periods of time at temperatures as low as -85.degree. C., losing its platelet aggregating activity when exposed to collagenase at 37.degree. C. or when heated at 100.degree. C. for fifteen minutes; containing the following average number of amino acid residues per 1,000 total amino acid residues:

which on SDS-PAGE electrophoresis produces bands characteristic of the following molecular weights:

322,000

300,000

250,000

220,000

163,000

132,000

116,000

100,000

61,500

51,500

45,000

36,000

13. A method as in claim 12 wherein the hemostatic agent is in a pharmaceutically acceptable carrier.

14. A method of controlling external bleeding from a wound or incision comprising contacting said wound or incision of an amount which is effective to control bleeding of an acid soluble, pepsin resistant, non-dialyzable, proteinaceous hemostatic agent isolated from equine arterial tissue characterized by the ability to enhance platelet aggregating activity in mammalian blood, stable for extended periods of time at temperatures as low as -85.degree. C., losing its platelet aggregating activity when exposed to collagenase at 37.degree. C. or when heated at 100.degree. C. for fifteen minutes; containing the following average number of amino acid residues per 1,000 total amino acid residues:

which on SDS-PAGE electrophoresis produces bands characteristic of the following molecular weights:

322,000

300,000

250,000

220,000

163,000

132,000

116,000

100,000

61,500

51,500

45,000

36,000

15. A method of detecting abnormal platelet function comprising contacting platelets in plasma or whole blood under test with an acid soluble, pepsin resistant, non-dialyzable, proteinaceous hemostatic agent isolated from equine arterial tissue characterized by the ability to enhance platelet aggregating activity in mammalian blood, stable for extended periods of time at temperatures as low as -85.degree. C., losing its platelet aggregating activity when exposed to collagenase at 37.degree. C. or when heated at 100.degree. C. for fifteen minutes; containing the following average number of amino acid residues per 1,000 total amino acid residues:

which on SDS-PAGE electrophoresis produces bands characteristic of the following molecular weights:

322,000

300,000

250,000

220,000

163,000

132,000

116,000

100,000

61,500

51,500

45,000

36,000

and comparing the aggregation response of said platelets to the response of normal platelets.

Details for Patent 4,347,243

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Research Corporation (New York, NY) 1999-08-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
McKinsey
McKesson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.